MedTrace Logo

Secondary Prevention in Acute Coronary Syndromes: A CALIBER Study

NCT01162187 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 400000

Last updated 2010-07-14

No results posted yet for this study

Summary

All contemporary guidelines for secondary prevention in acute coronary syndromes recommend a combination of aspirin, beta-blockers, ACE-inhibitors and statins. Yet underutilisation of these drugs is common. We do not know in detail what drives underutilisation, nor what its long term consequences are for survival after discharge from hospital. Also unknown is whether potential adverse effects of underutilisation are the same for individual secondary prevention drugs.

This study will assess the impact of secondary prevention underutilisation on survival.

Conditions

  • Acute Coronary Syndrome

Sponsors & Collaborators

  • Barts & The London NHS Trust

    collaborator OTHER

  • University of Leicester

    collaborator OTHER

  • University College, London

    lead OTHER

Principal Investigators

  • Owen M Nicholas, PhD · University College, London

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-07-31
Primary Completion
2010-06-30
Completion
2010-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01162187 on ClinicalTrials.gov